Evidence map›Paper›PMID 41855500›Full record

ArticleBlood advances2026

Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma.

Grace Baek, Gaurav Varma, Samuel Yamshon, Herman van Besien, Nancy L Bartlett, Marcus Watkins, Harsh R Shah, Kelsey Baron, Reid W Merryman, Ayo S Falade and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Grace BaekDivision of Hematology and Oncology, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0001-9972-4794
Gaurav VarmaDivision of Hematology and Medical Oncology, Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY.
Samuel YamshonDivision of Hematology and Oncology, Weill Cornell Medical College, New York, NY.ORCID 0000-0002-4616-8568
Herman van BesienDivision of Hematology and Oncology, Weill Cornell Medical College, New York, NY.ORCID 0009-0002-5456-6408
Nancy L BartlettDivision of Oncology, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0001-8470-394X
Marcus WatkinsDivision of Oncology, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0002-1224-3478
Harsh R ShahDivision of Hematology, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT.
Kelsey BaronDivision of Hematology, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT.ORCID 0000-0001-8115-7322
Reid W MerrymanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Ayo S FaladeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.ORCID 0000-0001-9201-6998
Jakub SvobodaLymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Sara PrischakLymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.ORCID 0009-0009-3097-7721
Christopher D'AngeloDivision of Hematology and Oncology, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE.ORCID 0000-0001-8456-0889
Joe D LukowskiDivision of Hematology and Oncology, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE.ORCID 0000-0001-7112-3591
Ranjana H AdvaniDivision of Medical Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Palo Alto, CA.
Austin H YeungDivision of Medical Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Palo Alto, CA.
Maya RosenbergDivision of Hematology and Medical Oncology, Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY.
Jenna VoutsinasDivision of Hematology and Oncology, Fred Hutchinson Cancer Center, Seattle, WA.
Mengyang DiDivision of Hematology and Oncology, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0001-6165-2617
Ryan LynchDivision of Hematology and Oncology, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0001-6703-0894
Christina PohDivision of Hematology and Oncology, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0003-3120-712X
Vikram RaghunathanDivision of Hematology and Oncology, Fred Hutchinson Cancer Center, Seattle, WA.
Mazyar ShadmanDivision of Hematology and Oncology, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0002-3365-6562
Stephen SmithDivision of Hematology and Oncology, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0001-5354-7593
Brian G TillDivision of Hematology and Oncology, Fred Hutchinson Cancer Center, Seattle, WA.
Chaitra UjjaniDivision of Hematology and Oncology, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0003-1977-1510
Catherine S DiefenbachDivision of Hematology and Medical Oncology, Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY.ORCID 0000-0003-1116-3246
Ajay K GopalDivision of Hematology and Oncology, Fred Hutchinson Cancer Center, Seattle, WA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41855500
PMCPMC13196555

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.